Spain· ES:03264001
ZEVALIN 1,6 mg/ml, EQUIPO REACTIVO PARA LA PREPARACION DE UN RADIOFARMACO PARA PERFUSION
A medicinal product containing ibritumomab, registered in Spain by Ceft Biopharma S.R.O..
Checked against AEMPS CIMA (Spain) on
Informational only — not a medical device.
The record
At a glance
AEMPS CIMA (Spain)- Active substance
- ibritumomab
- Manufacturer
- Ceft Biopharma S.R.O.
- Country
- Spain (ES)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- AEMPS CIMA (Spain)
- Last checked
- September 12, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Ibritumomab in 6 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of AEMPS CIMA (Spain). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e6d0218e-4fb8-473e-ab5b-5189279a8633 GET /v1/drugs/e6d0218e-4fb8-473e-ab5b-5189279a8633?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cpresc": "Uso Hospitalario",
"estado": "{\"aut\":1077058800000}",
"nregistro": "03264001",
"substance": "ibritumomab"
}See everything about ibritumomab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.